Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The EPIC Study
NCT07647432Phase 1Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elranatamab in plasmablastic lymphoma (PBL), sponsored by University of Illinois Chicago. Primary endpoints: Feasibility of giving Elranatamab in consolidation at 12 weeks, Complete Response at 6 months and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
elranatamab
03
Conditions
plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT07647432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647432.